• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Pluri Inc. filed SEC Form 8-K: Leadership Update

    9/11/25 8:00:28 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email
    false 0001158780 0001158780 2025-09-10 2025-09-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): September 11, 2025 (September 10, 2025)

     

    PLURI INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Nevada   001-31392   98-0351734
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    MATAM Advanced Technology Park    
    Building No. 5    
    Haifa, Israel   3508409
    (Address of Principal Executive Offices)   (Zip Code)

     

    011 972 74 710 8600

    (Registrant’s telephone number, including area code)

     

    Not applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Shares, par value $0.00001 per share   PLUR   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    On September 10, 2025, the board of directors (the “Board”) of Pluri Inc. (the “Company”) elected Mr. Eitan Ajchenbaum to serve as a member of the Board, effective immediately, to fill an existing vacancy on the Board created by the end of the service of Doron Birger following the results of the annual meeting of shareholders of the Company on June 30, 2025, to hold office until the next general meeting of shareholders of the Company at which directors are being elected or as set forth in the Company’s bylaws.

     

    Mr. Ajchenbaum, age 63, is a Certified Public Accountant (Israel) with over 30 years of senior executive and board experience in both public and private companies. Since June 2025, Mr. Ajchenbaum has served as Chief Financial Officer and Deputy Chief Executive Officer of WeSure Global Tech Ltd. (WESR.TA), a public company, traded on the Tel-Aviv Stock Exchange, focusing on the financial and insurance arenas. From 2011 until April 2024, he served as Chief Financial Officer and Treasurer of Berkshire Hathaway Guard (and since 2007, as a board member in most of the Berkshire Hathaway Guard’s group of companies), an insurance group, where he previously held the role of Chief Risk Officer and was responsible for finance, accounting, corporate legal, investments, internal audit, and risk management and more. Earlier in his career, Mr. Ajchenbaum held senior finance positions including Chief Financial Officer of Bezeq International Ltd. (BZQIY.TA), Executive Vice President of Direct Insurance Ltd. (DRIN.TA), and Finance and Organization Manager at Analyst Investment Company Ltd. (ANLT.TA), each a publicly traded company in Israel. Mr. Ajchenbaum began his career as an auditor at Kesselman & Kesselman (currently PwC Israel). Mr. Ajchenbaum holds a B.A. in Accounting and Economics from Tel-Aviv University.

     

    Mr. Ajchenbaum will serve as a non-executive director and will be entitled to the rights and privileges afforded to other non-executive directors, including receipt of information, reimbursement of expenses, and coverage under the Company’s directors’ and officers’ insurance policies. Mr. Ajchenbaum has been appointed as a member and Chairman of the Audit Committee of the Board, designated as an audit committee financial expert (as defined under Item 407(c) under Regulation S-K) and as sole member of the Investment Committee of the Board.

     

    There are no arrangements or understandings between Mr. Ajchenbaum and any other person pursuant to which he was selected as a director. Additionally, Mr. Ajchenbaum does not have any family relationship with any director or executive officer of the Company and does not have any direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K.

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PLURI INC.
       
    Date: September 11, 2025 By: /s/ Liat Zalts
      Name:  Liat Zalts
      Title: Chief Financial Officer

     

     

    2

     

    Get the next $PLUR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico

    State-backed collaboration outlines a multi-phase, capital-light path from cell line development to pilot-scale biofarming and evaluation of commercial-scale manufacturing in ChiapasCoffeesai leverages Pluri's proprietary 3D cell expansion platform and two decades of expertise to pioneer cell-based coffee solutions resilient to climate change, land constraints, and market volatilityThe global coffee market exceeded $250B in 2024 and is projected to surpass $350B by 2030 (CAGR 5.3% from 2025 to 2030), creating a significant opportunity for scalable, cost-competitive production HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE:

    10/8/25 9:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

    NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. This partnership supports

    5/27/25 7:00:00 AM ET
    $BCLI
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

    Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer an

    5/15/25 7:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    SEC Filings

    View All

    SEC Form EFFECT filed by Pluri Inc.

    EFFECT - Pluri Inc. (0001158780) (Filer)

    9/26/25 12:15:27 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Pluri Inc.

    S-3 - Pluri Inc. (0001158780) (Filer)

    9/17/25 5:27:34 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Pluri Inc.

    S-8 - Pluri Inc. (0001158780) (Filer)

    9/17/25 4:56:56 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Ajchenbaum Eitan

    3 - Pluri Inc. (0001158780) (Issuer)

    9/22/25 5:27:37 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    7/1/25 4:00:11 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Shemesh-Rasmussen Maital was granted 11,173 shares, increasing direct ownership by 154% to 18,445 units (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    2/27/25 4:00:19 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    7/1/25 4:00:11 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    View All

    Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

    HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

    3/6/24 7:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

    HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

    7/13/23 2:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Financials

    Live finance-specific insights

    View All

    BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

    Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

    11/11/24 6:00:00 AM ET
    $BCLI
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    2/13/24 4:34:49 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    2/1/24 4:02:29 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    9/15/23 4:00:03 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care